PPARγ is reduced in the airways of non-CF bronchiectasis subjects and is inversely correlated with the presence of Pseudomonas aeruginosa

PLoS One. 2018 Aug 16;13(8):e0202296. doi: 10.1371/journal.pone.0202296. eCollection 2018.

Abstract

Background: Chronic airway inflammation in conditions such as cystic fibrosis (CF) and non-CF bronchiectasis is characterised by a predominant neutrophilic inflammatory response, commonly due to the presence of pathogenic bacteria such as Pseudomonas aeruginosa. We hypothesised that down-regulation of the anti-inflammatory nuclear transcription regulator peroxisome proliferator-activated receptor gamma (PPARγ in non-CF bronchiectasis subjects may explain why this exuberant neutrophilic inflammation is able to persist unchecked in the inflamed airway.

Methods: PPARγ gene expression was assessed in bronchoalveolar lavage fluid (BAL) of 35 macrolide naïve non-CF bronchiectasis subjects and compared with that in 20 healthy controls. Human RNA was extracted from pelleted BAL and PPARγ expression was determined by reverse-transcription quantitative PCR. Bacterial DNA was extracted from paired induced sputum and total bacterial load was determined by 16S rRNA qPCR. Quantification of individual bacterial species was achieved by qPCR.

Results: PPARγ expression was lower in subjects with non-CF bronchiectasis compared with healthy control subjects (control: 1.00, IQR 0.55-1.44, n = 20 vs. Bronchiectasis: 0.49, IQR 0.12-0.89; n = 35; p<0.001, Mann-Whitney U test). This lower PPARγ expression correlated negatively with Pseudomonas aeruginosa (r = -0.53, n = 31; p = 0.002). No significant association was seen between PPARγ and total bacterial levels or levels Haemophilus influenzae.

Conclusion: PPARγ is expressed in low levels in the airways of non-CF bronchiectasis subjects, despite an aggressive inflammatory response. This low level PPARγ expression is particularly associated with the presence of high levels of P. aeruginosa, and may represent an intrinsic link with this bacterial pathogen.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Bacterial Load
  • Bronchiectasis / immunology*
  • Bronchiectasis / microbiology*
  • Bronchoalveolar Lavage Fluid / cytology
  • Bronchoalveolar Lavage Fluid / immunology*
  • Bronchoalveolar Lavage Fluid / microbiology*
  • Female
  • Gene Expression Regulation
  • Humans
  • Male
  • Middle Aged
  • PPAR gamma / metabolism*
  • Pseudomonas aeruginosa* / genetics

Substances

  • PPAR gamma

Grants and funding

GR is supported by a Matthew Flinders Research Fellowship, and the study was funded by Mater Respiratory Research Trust Fund, Mater Foundation Betty McGrath Clinical Research Fellowship (LDB). The authors received no specific funding for this work, however Dr Lucy Burr, Dr Simon Bowler and Rebecca Keating are employed by Mater Misericordiae Health Services Ltd. This is a not-for-profit hospital and health services company. The funder provided support in the form of salaries for the authors listed above, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the ‘author contributions’ section.